• Explore /
  • Poster
  • / Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.

Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.

Abstract Poster

Authors

Alicia Morgans

Alicia K. Morgans

Dana-Farber Cancer Institute, Boston, MA

Alicia K. Morgans , Christopher Sweeney , Christopher J.D. Wallis , Susan Halabi , Andrew J. Armstrong , Frank Verholen , Jorge A. Ortiz , Anja Schmall , Shankar Srinivasan , Marc-Oliver Grimm

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

TBC

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5044)

DOI

10.1200/JCO.2022.40.16_suppl.5044

Abstract #

5044

Poster Bd #

228

Abstract Disclosures

Similar Posters

First Author: Karim Fizazi

First Author: Alicia K. Morgans

First Author: Boris A. Hadaschik

Poster

2023 ASCO Genitourinary Cancers Symposium

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

First Author: Daniel J. George